D. Medical Receives CE Mark Approval for "Spring Zone" Durable Insulin Pump
11 Janeiro 2012 - 10:30AM
D. Medical Industries Ltd. (Nasdaq:DMED) (TASE:DMED) ("D. Medical"
or "Company"), a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery, today
announced that the Company, through its wholly owned subsidiary
Spring Health Solution Ltd., received a CE Mark approval for its
Spring™ Zone Insulin Delivery System. "Spring Zone" replaces D.
Medical's first generation Spring ADI insulin pump.
The proprietary Intellispring™ technology at the heart of the
"Spring Zone" Insulin Delivery System results in unique performance
advantages such as superior blockage and detachment detection,
environmental (pressure and temperature) adaptability and
continuous insulin dose delivery check. This mechanism, backed by
the Total Line Control™ (TLC) safety check system, enables failsafe
operation and exceptional reliability for continuously controlled
and monitored insulin delivery.
Other key design features that differentiate the Spring Zone
from all other models on the market make it the smallest, lightest
and quietest durable insulin pump.
Hezkiah Tsoory, D. Medical's Chief Operating Officer,
commented: "The CE Mark approval is an important milestone
that comes at the perfect time, just as the company is looking for
a worldwide partner with whom to commercialize its pump technology.
We continue gaining ground with European and North American market
acceptance of the Spring Universal Infusion Set. Our
accomplishments in refining and scaling our manufacturing capacity,
as well as widening the distribution channels, will pave the way
for our next round of innovations."
About D. Medical
D. Medical is a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery. D.
Medical has developed durable and semi-disposable insulin pumps,
which continuously infuse insulin into a patient's body, using its
proprietary spring-based delivery technology. D. Medical believes
that its spring- based delivery mechanism is cost-effective
compared to the motor and gear train mechanisms that drive
competitive insulin pumps and also allows it to incorporate certain
advantageous functions and design features in its insulin pumps. D.
Medical has also developed an infusion set for insulin pumps and is
focusing its research and development efforts on the development of
next generation insulin pumps and a device that will combine a
continuous glucose monitoring system and an insulin pump on
the same patch. For more information, please visit
http://www.dmedicalindustries.com (corporate) and
http://www.springnow.com (healthcare professionals, patients and
caregivers).
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by the Israeli Securities Law, 1968, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) that involve risks and
uncertainties. These statements include forecasts, goals,
uncertainties and assumptions and relate, inter alia, to D.
Medical's future expectations in connection with its level of
sales, markets penetration, readiness of its production lines and
timing of markets penetration. The forward-looking statements are
based on D. Medical's current expectations and beliefs which are
based on, among other things, its analysis of publicly available
information and market research reports. All forward-looking
statements are subject to certain risks, uncertainties and
assumptions that could cause actual results to differ materially
from those described in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the impact of
general economic conditions, competitive products, product demand,
the performance of D. Medical's Swedish distributor and contract
manufacturer, regulatory trends and approvals and healthcare reform
legislation. If one or more of these risks and/or uncertainties
materialize, or if the underlying assumptions prove to be
incorrect, D. Medical's actual results, performance or achievements
could differ materially from those expressed in, or implied by, any
such forward-looking statements or results which are based upon
such assumptions. No assurances can be given that any of the events
anticipated by the forward-looking statements will transpire or
occur, or if any of them transpire or occur, what impact it will
have on D. Medical's results of operations or financial condition.
D. Medical does not undertake to update any forward-looking
statements.
CONTACT: Company Contact:
Amir Loberman
Chief Financial Officer
D. Medical Industries Ltd.
T: +972-73-2507100
info@springnow.com
North American Investor Contact:
Stephen Kilmer
T: 212-618-6347
M: 905-906-6908
stephen@dmedicalindustries.com
Israeli Investor Relations:
Michal Efraty
T: +972-3-6950380
M: +972-52-3044404
michal@efraty.com
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024